David Bredt - 17 Feb 2026 Form 4 Insider Report for Rapport Therapeutics, Inc. (RAPP)

Reporting relationship: Chief Scientific Officer
Issuer ticker: RAPP
Reported as of: 17 Feb 2026
Net transaction value: -$235,855
SEC form: 4
Accepted by SEC: 19 Feb 2026, 19:05:23 UTC
Prior SEC filing: 04 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Troy Ignelzi, Attorney-in-Fact

Key filing fact

David Bredt filed Form 4 for Rapport Therapeutics, Inc. (RAPP) on 19 Feb 2026.

Key facts

This page summarizes David Bredt's Form 4 filing for Rapport Therapeutics, Inc. (RAPP).
5 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 19 Feb 2026, 19:05.

Change

Previous filing in this sequence was filed on 04 Feb 2026.
Current net transaction value: -$235,855.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002022087 Primary reporting owner

Bredt David

Relationship: Chief Scientific Officer
Address: RAPPORT THERAPEUTICS, INC., 99 HIGH STREET, SUITE 2100, BOSTON
Signature: /s/ Troy Ignelzi, Attorney-in-Fact
Signature date: 19 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RAPP transaction

Common Stock

Sale

Transaction value: $25,219
Shares: -900
Change %: -0.23%
Price: $28.02
Shares after: 394,675
Date: 17 Feb 2026
Ownership: Direct
Footnotes: F1, F2

RAPP transaction

Common Stock

Sale

Transaction value: $156,328
Shares: -5,400
Change %: -1.4%
Price: $28.95
Shares after: 389,275
Date: 17 Feb 2026
Ownership: Direct
Footnotes: F1, F3

RAPP transaction

Common Stock

Sale

Transaction value: $65,108
Shares: -2,200
Change %: -0.57%
Price: $29.59
Shares after: 387,075
Date: 17 Feb 2026
Ownership: Direct
Footnotes: F1, F4

RAPP transaction

Common Stock

Options Exercise

Transaction value: $10,800
Shares: +6,000
Change %: +1.6%
Price: $1.80
Shares after: 393,075
Date: 19 Feb 2026
Ownership: Direct
Footnotes: F5

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RAPP transaction Derivative

Stock Options (Right to Buy)

Options Exercise

Transaction value: $0
Shares: -6,000
Change %: -6.4%
Price: $0.000000
Shares after: 88,080
Date: 19 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 6,000
Exercise price: $1.80
Footnotes: F6

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 6 footnotes

Footnote F1

These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024.

Footnote F2

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.39 to $28.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

Footnote F3

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.40 to $29.36, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

Footnote F4

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.45 to $29.81, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

Footnote F5

Transaction involved a cash exercise of options to purchase shares of the Issuer's common stock. No shares of the Issuer's common stock were sold as part of this transaction.

Footnote F6

25% of the shares underlying this option vested and became exercisable on August 7, 2024, with the remaining shares vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.